Tab. V.
Adjusted variables in assessment relationship of statin use and mortality of OC.
| Publication first author | Year | Adjusted variables |
|---|---|---|
| Couttenier [13] | 2017 | Age at diagnosis, year of diagnosis, comorbidities, cancer stage, and cancer treatments |
| Chen [21] | 2016 | Age, Federation International de Gynecologic at d’Obstétrique (FIGO) stage, tumor grade, histological subtype, cytoreductive surgery, cycles of chemotherapy, comorbidities (hypercholesterolemia and cardiovascular diseases) |
| Elmore [15] | 2008 | Age, diabetes mellitus, grade, stage, suboptimal cytoreduction |
| Verdoodt [19] | 2017 | Age at diagnosis, clinical stage, and year of diagnosis, tumour histology, chemotherapy, highest achieved education, disposable income, marital status, non-statin drug use and several comorbidities |
| Vogel [14] | 2017 | Age, race, median household income, stage, histology, platinum therapy, Charlson index, heart disease, diabetes, obesity, dyslipidemia |
| Harding [36] | 2019 | Age at diagnosis, year at diagnosis, race/ethnicity, marital status, surgical treatment received, grade of disease, stage at diagnosis, census tract poverty level, location of residence, Deyo-Charlson comorbidity score, comorbidities |
| Habis [35] | 2014 | Age, race, BMI, smoking status, comorbidities, physical status scores class, surgery characteristics, histologic subtype, FIGO stage, tumor site and grade of disease |
| Bar [20] | 2016 | Age, grade of disease, neoadjuvant chemotherapy, beta-blockers, aspirin, metformin, beta-blockers and comorbidity |
| Lavie [11] | 2013 | Age |